COMPANY
Merlin Biotech Inc.
NIH awards 2
- NIH award 1R43DE035421-01 FY2026: $400,000 awarded for that fiscal year; activity R43 (SBIR); PI HENRICH, IAN; recipient as written: MERLIN BIOTECH INC, DOYLESTOWN, PA. Investigating Enhanced Activity of MER-101 in H source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N91025C00025-0-9999-1 FY2025: $355,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI n/a; recipient as written: MERLIN BIOTECH INC, DOYLESTOWN, PA. SBIR FY25 Concept Awa source ↗
Funding and NIH signals
- SEC Form D raise Raised $50K in debt securities (Form D filed Aug 11, 2026). SEC Form D 0002149714-26-000001 (Aug 11, 2026)
Evidence (1 event)
- Aug 11, 2026 · SEC Form D 0002149714-26-000001
Name of Issuer: Merlin Biotech, Inc.; CIK: 2149714; Address: Doylestown, PA; Submission type: D; Filing date: 2026-08-11; Industry Group: Biotechnology; Date of First Sale: 2026-06-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 50000; Total Amount Sold: 50000; Federal exemptions: 06b
- Aug 11, 2026 · SEC Form D 0002149714-26-000001
- NIH award NIH awarded $400K (SBIR Phase I 1R43DE035421-01, new, notice Sep 11, 2026). NIH RePORTER 1R43DE035421-01 (Sep 11, 2026)
Evidence (1 event)
- Sep 11, 2026 · NIH RePORTER 1R43DE035421-01
Organization: MERLIN BIOTECH INC; City/State: DOYLESTOWN, PA; Project number: 1R43DE035421-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 400000; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Investigating Enhanced Activity of MER-101 in HPV+ Head and Neck Cancer; Organization type: Domestic For-Profits
- Sep 11, 2026 · NIH RePORTER 1R43DE035421-01